Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Business Wire•03/10/2026•15:40 ET
13
Key Highlights
- ➤Rina-S achieved 45.9% confirmed objective response rate in 109 PROC patients
- ➤Median duration of response reached 12.1 months, with 51% responding at one year
- ➤Median progression-free survival was 9.5 months in the Phase 2 cohort
- ➤Antitumor activity occurred regardless of FRα expression or prior mirvetuximab treatment
- ➤Treatment discontinuation due to adverse events occurred in 5.5% of participants
Expert Statements
Elizabeth K. Lee, M.D., study investigator and medical oncologist, Dana-Farber Cancer Institute
“The antitumor activity and durability observed with Rina-S in this heavily pretreated population are encouraging and suggest the potential to meaningfully impact outcomes for patients facing a particularly challenging stage of disease.”
Tahamtan Ahmadi, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab
“These findings, including the observed antitumor activity, duration of response, and the first progression-free survival data reported for the program, as well as the manageable tolerability, reinforce the potential of Rina-S.”
Genmab Announces Rinatabart Sesutecan (Rina-S(®)) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
* Treatment with Rina-S(®) 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC)
Get started
Create a free account to read the full story.